Fluorine-modified sialyl-Tn-CRM197 vaccine elicits a robust immune response

Area of Science:

• Immunology
• Oncology
• Vaccine Development

Background:

• Therapeutic vaccines targeting tumor-associated carbohydrate antigens are promising for epithelial carcinoma but face limitations due to poor immunogenicity.
• Sialyl-Tn (STn) is a key tumor antigen in epithelial cancers, making it a target for immunotherapy.

Purpose of the Study:

• To investigate the immunological activity of a fluoro-substituted Sialyl-Tn (F-STn) analogue conjugated to CRM197 (F-STn-CRM197).
• To evaluate the potential of F-STn-CRM197 as a cancer vaccine for immunotherapy.

Main Methods:

• Conjugation of a fluoro-substituted Sialyl-Tn (F-STn) analogue to CRM197.
• Assessment of immunological activity, including lymphocyte proliferation, cytokine production (IFN-γ, IL-4), and antibody generation in the presence or absence of adjuvant.
• Evaluation of antisera's ability to recognize STn-positive tumor cells and induce antibody-dependent cell-mediated cytotoxicity (ADCC) and complement-dependent cytotoxicity (CDC).

Main Results:

• F-STn-CRM197 demonstrated significantly greater immunogenicity compared to non-fluorinated STn-CRM197.
• The vaccine enhanced both cellular and humoral immunity, characterized by increased antigen-specific lymphocyte proliferation and a mixed Th1/Th2 response.
• Antisera from F-STn-CRM197 immunization recognized STn-positive tumor cells and mediated cancer cell lysis via ADCC and CDC pathways.

Conclusions:

• The F-STn-CRM197 conjugate represents a potent vaccine candidate for cancer immunotherapy.
• This novel vaccine may hold potential for the prophylactic prevention of epithelial cancers.